S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Lapatinib and everolimus may stop the growth of cancer cells by blocking some of
the enzymes needed for cell growth. Everolimus may also stop the growth of cancer cells by
blocking blood flow to the cancer. Giving lapatinib together with everolimus may kill more
cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib and
everolimus in treating patients with advanced solid tumors or non-Hodgkin's lymphoma.